Episode 66. International Myeloma Society 2025 Annual Meeting Updates with Dr. Alfred Garfall: The Bispecific Bonanza

About this episode

This episode covers key clinical trial updates from the 2025 International Myeloma Society Annual Meeting, focusing on bispecific antibodies and novel immunotherapies.

This episode provides comprehensive coverage of key clinical trial updates from the 2025 International Myeloma Society (IMS) Annual Meeting in Toronto, with special focus on bispecific antibodies and novel immunotherapies across the multiple myeloma disease continuum—from smoldering disease through relapsed/refractory settings. Dr. Alfred Garfall provides expert commentary on study design, efficacy, safety considerations, and clinical implications. Topics Covered 1. SMOLDERING MULTIPLE MYELOMA LINKER-SMM1 Phase 2, open-label study of linvoseltamab monotherapy (200 mg) in patients with high-risk smoldering multiple myeloma by 20/2/20 or PETHEMA criteria, with 2-year treatment duration. Discussion Points: Appropriateness of 2-year treatment duration for precursor condition Efficacy and MRD-negative rates Safety considerations in asymptomatic population Patient selection if available today 2. NEWLY DIAGNOSED MULTIPLE MYELOMA MajesTEC-5 Phase 2 trial evaluating three teclistamab-daratumumab-based induction regimens in 49 transplant-eligible NDMM patients, followed by auto-transplant and fixed-duration Tec-Dara maintenance. Discussion Points: Post-induction MRD-negativity rates with…

People in this episode

Hosts: Rajshekhar Chakraborty, Ashwin Kishtagari, Edward Cliff

Guest: Dr. Alfred Garfall

Topics covered

• multiple myeloma
• clinical trials
• bispecific antibodies
• immunotherapies
• treatment updates
• safety considerations

Keywords

• multiple myeloma
• clinical trials
• bispecific antibodies
• immunotherapy
• safety considerations
• treatment duration
• MRD-negativity

Mentioned in this episode

Organizations: International Myeloma Society, PETHEMA, MajesTEC-5, MagnetisMM-6

Products: linvoseltamab, teclistamab, daratumumab, elranatamab, bortezomib

Places: Toronto

More episodes of Blood Cancer Talks

• Episode 71. Management of Newly Diagnosed Multiple Myeloma with Dr. Vincent Rajkumar · May 19, 2026 · 52 min
• Episode 70. ASH 2025 Myeloid Neoplasm Roundup with Dr. Curtis Lachowiez · February 27, 2026 · 57 min
• Episode 69. ASH 2025 Lymphoma Roundup with Dr. Carla Casulo · January 22, 2026 · 44 min
• Episode 68. ASH 2025 Myeloma Special: MajesTEC-3 and the Bispecific Revolution with Dr. Luciano Costa · January 2, 2026 · 46 min
• Episode 67. Management of CMV in Hematologic Malignancies · November 23, 2025 · 40 min
• Episode 65. Circulating Tumor DNA in DLBCL with Dr. Ash Alizadeh and Dr. David Russler-Germain · September 24, 2025 · 53 min